Etanercept, Recombinant human TNFR, Fc tagged

Specification

• Cat#: THP-0112
• Product Name: Etanercept, Recombinant human TNFR, Fc tagged
• Cas No: 185243-69-0
• Description: Etanercept consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of the product contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. It encodes 934 amino acids, expressed in CHO Cells.
• Sequences: LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
• Species: Human
• Molecular Weight: 51234.9 Da
• Source: CHO
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: C2224H3475N621O698S36
• Endotoxin: <0.001 EU per 1 μg of the peptide by the LAL method
• Application: The product is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more disease-modifying anti-rheumatic drugs. The product is also used to improve psoriatic arthritis and ankylosing spondylitis.
• Concentration: 50mg/ml

Pharmaceutical Information

• Pharmaceutical Application: Etanercept
• Targets: Target 1. Tumor necrosis factor; Target 2. Tumor necrosis factor receptor superfamily member 1B; Target 3. High affinity immunoglobulin gamma Fc receptor I; Target 4. Low affinity immunoglobulin gamma Fc region receptor III-A; Target 5. Low affinity immunoglobulin gamma Fc region receptor II-a; Target 6. Low affinity immunoglobulin gamma Fc region receptor II-b; Target 7. Low affinity immunoglobulin gamma Fc region receptor II-c; Target 8. Lymphotoxin-alpha; Target 9. Low affinity immunoglobulin gamma Fc region receptor III-B; Target 10. Complement C1s subcomponent; Target 11. Complement C1r subcomponent; Target 12. Complement C1q subcomponent subunit A; Target 13. Complement C1q subcomponent subunit B; Target 14. Complement C1q subcomponent subunit C